Oncbiomune, a biotechnology company specializing in innovative cancer treatment, has proprietary rights to a breast cancer vaccine (patent #5,478,556) and prostate cancer vaccine (patent pending), as well as a (patent pending) process for the growth of cancer tumor cells. Oncbiomune’s principals, Robert L. Elliott, M.D., Ph.D., Jonathan F. Head, Ph.D., have the knowledge of an untapped market for the treatment of cancer with antisense and see that the mass production of antisense as a very lucrative and high revenue-generating prospect. Oncbiomune’s technology is safe, and utilizes proven methods of treatment to provide optimal success of patient recovery. Oncbiomune will provide patients and doctors the resources needed to reduce cancer growth and increase survival rate among diagnosed patients.

Oncbiomune’s stand-alone technology, utilized by the transferrin transport technology and vaccination of women with breast cancer, has applications growing to encompass other solid tumors. The utilization of the technology gathered will benefit cancer research and further product development that will include the mass production of antisense for the expected increase in the volume of its use in future treatments and research and development.

The technology of Onciomune begins with diseases of the breast as the foundation, but also provides a focus involving prostate cancer and other solid tumors. Oncbiomune has the technology to provide the world with a better standard for laboratory-applied research procedures. The forecasted start up potential and the projected market for The Company products are optimal for success in the biotechnological industry.